

## DAFTAR PUSTAKA

- Badan Penelitian dan Pengembangan Kesehatan, Kementerian Kesehatan Republik Indonesia. Laporan Riset Kesehatan Dasar (Riskesdas) 2018.
- Barr WG. Uric Acid. In: Walker HK, Hall WD, Hurst JW, editors. *Clinical Methods: The History, Physical, and Laboratory Examinations*. 3rd edition. Boston: Butterworths; 1990. Chapter 165. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK273/>
- Dungga, E. F. (2022). Pola Makan dan Hubungannya Terhadap Kadar Asam Urat. *Jambur Nursing Journal*, 4(1), 7–15. <https://doi.org/10.37311/jnj.v4i1.13462>
- Fathallah-Shaykh SA, Cramer MT. Uric acid and the kidney. *Pediatr Nephrol*. 2014 Jun;29(6):999-1008. doi: 10.1007/s00467-013-2549-x. Epub 2013 Jul 4. PMID: 23824181.
- George, C., Leslie, S. W., Minter, D. A. (2023) 'Hyperuricemia', in StatPearls. Treasure Island (FL): StatPearls. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK459218/> (Accessed: 15 Maret 2024).
- Giordano C, Karasik O, King-Morris K, Asmar A. Uric Acid as a Marker of Kidney Disease: Review of the Current Literature. *Dis Markers*. 2015;2015:382918. doi: 10.1155/2015/382918. Epub 2015 May 27. PMID: 26106252; PMCID: PMC4461768.
- Kannuthurai V, Gaffo A. Management of Patients with Gout and Kidney Disease: A Review of Available Therapies and Common Missteps. *Kidney360*. 2023 Sep 1;4(9):e1332-e1340. doi: 10.34067/KID.000000000000221. PMID: 37526648; PMCID: PMC10550007.
- Kartika, H. (2022, July 9). Direktorat Jenderal Pelayanan Kesehatan. [https://yankes.kemkes.go.id/view\\_artikel/237/asam-urat-bisa-menyerang-ginjal](https://yankes.kemkes.go.id/view_artikel/237/asam-urat-bisa-menyerang-ginjal)
- Kovesdy C. P. (2022). Epidemiology of chronic kidney disease: an update 2022. *Kidney international supplements*, 12(1), 7–11. <https://doi.org/10.1016/j.kisu.2021.11.003>
- Li, L., Zhang, Y., & Zeng, C. (2020). Update on the epidemiology, genetics, and therapeutic options of hyperuricemia.
- Parisa, N., Kamaluddin, M. T., Saleh, M. I., & Sinaga, E. (2023). The inflammation process of gout arthritis and its treatment. *Journal of advanced pharmaceutical technology & research*, 14(3), 166–170. [https://doi.org/10.4103/japtr.japtr\\_144\\_23](https://doi.org/10.4103/japtr.japtr_144_23)
- Perhimpunan Reumatologi Indonesia. (2018). Rekomendasi Pedoman Diagnosis dan Pengelolaan Gout.
- Perhimpunan Reumatologi Indonesia. (2020). *Buku Saku Reumatologi*. Jakarta: Perhimpunan Reumatologi Indonesia bekerja sama dengan Keio University.
- Ragab, G., Elshahaly, M., & Bardin, T. (2017). Gout: An old disease in new perspective-A review. <https://doi.org/10.1016/j.jare.2017.04.008>
- Satyanarayana, P. et al. (2022) 'Chronic Kidney Disease', in StatPearls. Treasure Island (FL): StatPearls. Available

- at: <https://www.ncbi.nlm.nih.gov/books/NBK535404/> (Accessed: 16 Maret 2024).
- National Kidney Foundation. How to Classify CKD [Internet]. National Kidney Foundation. 2024. Available from: <https://www.kidney.org/professionals/explore-your-knowledge/how-to-classify-ckd>
- Singh, J. A., & Gaffo, A. (2020). Gout epidemiology and comorbidities. *Seminars in Arthritis and Rheumatism*, 50, S11–S16. <https://doi.org/10.1016/j.semarthrit.2020.04.008>
- Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature. *Curr Opin Rheumatol*. 2011 Mar;23(2):192-202. doi: 10.1097/BOR.0b013e3283438e13. PMID: 21285714; PMCID: PMC4104583.
- Sissons, Claire. (2023, Maret 2). What are the effects of high and low uric acid levels?. *Medical News Today*. Diakses pada [16 Maret 2024], dari [<https://www.medicalnewstoday.com/articles/uric-acid-level>].
- Otani, N., Ouchi, M., Misawa, K., Hisatome, I., & Anzai, N. (2022). Hypouricemia and Urate Transporters. *Biomedicines*, 10(3), 652. <https://doi.org/10.3390/biomedicines10030652>
- Skoczyńska M, Chowaniec M, Szymczak A, Langner-Hetmańczuk A, Maciążek-Chyra B, Wiland P. Pathophysiology of hyperuricemia and its clinical significance - a narrative review. *Reumatologia*. 2020;58(5):312-323. doi: 10.5114/reum.2020.100140. Epub 2020 Oct 29. PMID: 33227090; PMCID: PMC7667948.
- So, A. K., & Martinon, F. (2017). Inflammation in gout: mechanisms and therapeutic targets. *Nature reviews. Rheumatology*, 13(11), 639–647. <https://doi.org/10.1038/nrrheum.2017.155>
- Son CN, Kim JM, Kim SH, Cho SK, Choi CB, Sung YK, Kim TH, Bae SC, Yoo DH, Jun JB. Prevalence and possible causes of hypouricemia at a tertiary care hospital. *Korean J Intern Med*. 2016 Sep;31(5):971-6. doi: 10.3904/kjim.2015.125. Epub 2016 Mar 9. PMID: 26956409; PMCID: PMC5016282.
- Sudoyo AW, Setyohadi B, Alwi I, Simadibrata M, Setiadi S, editors. *Buku Ajar Ilmu Penyakit Dalam Jilid I Edisi IV*. Jakarta: Departemen Ilmu Penyakit Dalam FKUI; 2007.
- University of Rochester Medical Center [Internet]. Rochester (NY): University of Rochester Medical Center; c2022. *Health Encyclopedia: Uric Acid (Blood)*; [cited 2022 Sep 22]; [about 5 screens]. Available from: [https://www.urmc.rochester.edu/encyclopedia/content.aspx?contenttypeid=167&contentid=uric\\_acid\\_blood](https://www.urmc.rochester.edu/encyclopedia/content.aspx?contenttypeid=167&contentid=uric_acid_blood)
- Vaidya SR, Aeddula NR. Chronic Kidney Disease. [Updated 2022 Oct 24]. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK535404/>
- Rahayu, C., Permana, A. and Seprima, F. (2022) “Studi Gambaran Kadar Asam Urat, Ureum dan Kreatinin Pada Pasien Gagal Ginjal Kronik”, *Anakes : Jurnal Ilmiah Analisis Kesehatan*, 8(1), pp. 1–10. doi: 10.37012/anakes.v8i1.871.

- Prakash, S., & O'Hare, A. M. (2009). Interaction of aging and chronic kidney disease. *Seminars in nephrology*, 29(5), 497–503. <https://doi.org/10.1016/j.semnephrol.2009.06.006>
- Delima, Tjitra, E., Tana, L., Halim, F. S., Ghani, L., Siswoyo, H., Idaiani, S., Andayasari, L., Widowati, L., Gitawati, R., Sihombing, M., Notohartoyo, I. T., Sintawati, S., Jovina, T. A., Karyana, M., Nugroho, P., Wibisono, D., Sarwono, J., Agustin, H., ... Siswanto, S. (2017). Faktor Risiko Penyakit Ginjal Kronik: Studi Kasus Kontrol di Empat Rumah Sakit di Jakarta Tahun 2014. *Buletin Penelitian Kesehatan*, 45(1). <https://doi.org/10.22435/bpk.v45i1.5771.17-26>
- Hervinda, S., Novadian, N., & Tjekyan, R.M. (2014). Prevalensi dan Faktor Risiko Penyakit Ginjal Kronik di RSUP Dr. Mohammad Hoesin Palembang Tahun 2012.
- Hsieh, M. and D.A. Power. Abnormal Renal Function and Electrolyte Disturbance in Older people. *Journal of Pharmacy Practice and Research* 2009;39 (3): 230-234
- Jeyaruban, A., Hoy, W., Cameron, A., Healy, H., Wang, Z., Zhang, J., & Mallett, A. (2021). Hyperuricaemia, gout and allopurinol in the CKD Queensland registry. *Journal of nephrology*, 34(3), 753–762. <https://doi.org/10.1007/s40620-020-00937-4>
- Levey, A. S., & Coresh, J. (2012). Chronic kidney disease. *Lancet (London, England)*, 379(9811), 165–180. [https://doi.org/10.1016/S0140-6736\(11\)60178-5](https://doi.org/10.1016/S0140-6736(11)60178-5)
- Lubis, R. And Thristy, I. (2023) “Perbandingan Kadar Asam Urat Dan Laju Filtrasi Glomerulus (LFG) pada Pasien Gagal Ginjal Kronik Sebelum dan Sesudah Hemodialisa”, *Jurnal Ilmiah Kohesi*, 7(1), pp. 47-54. Available at: <https://kohesi.sciencemakarioz.org/index.php/JIK/article/view/382> (Accessed: 8November2024).
- Mantiri, I. N. R. I., Rambert, G. I., & Wowor, M. F. (2017). Gambaran Kadar Asam Urat pada Pasien Penyakit Ginjal Kronik Stadium 5 yang Belum Menjalani Hemodialisis. In *Jurnal e-Biomedik (eBm)* (Vol. 5, Issue 2).
- Mohammed, E., Browne, L. D., Kumar A U, A., Adeeb, F., Fraser, A. D., & Stack, A. G. (2019). Prevalence and treatment of gout among patients with chronic kidney disease in the Irish health system: A national study. *PloS one*, 14(1), e0210487. <https://doi.org/10.1371/journal.pone.0210487>
- Pranata, P. B. (2013). Hubungan Kadar Asam Urat Dalam Darah Pada Penderita Penyakit Ginjal Kronik Dengan Kejadian Artritis Gout Di RSUD Dr.Moewardi Surakarta.
- Purba, S. (2021) “GAMBARAN KADAR ASAM URAT PADA PENDERITA GAGAL GINJAL KRONIK DI RUMAH SAKIT BINA KASIH PEKANBARU”, *The Indonesian Journal of Medical Laboratory*, 2(1), pp. 6-11. Available at: <https://ijml.journalsenior.com/index.php/ijml/article/view/13> (Accessed: 8November2024).
- Susanti, D. A. R. (2020) “Analisis Kadar Asam Urat pada Penderita Gagal Ginjal Kronis (GGK)”, *International Journal of Applied Chemistry Research*, 1(2), pp. 35–39. doi: 10.23887/ijacr.v1i2.28725.
- Tan, V. S., Garg, A. X., McArthur, E., Lam, N. N., Sood, M. M., & Naylor, K. L. (2017). The 3-Year Incidence of Gout in Elderly Patients with CKD. *Clinical journal of the*

*American Society of Nephrology* : *CJASN*, 12(4), 577–584.  
<https://doi.org/10.2215/CJN.06790616>

Sarpal, V. (2017). Serum Uric Acid Level in Patients with Chronic Kidney Disease: A Prospective Study. *International Journal of Scientific Study*, 4, 11.  
<https://doi.org/10.17354/ijss/2017/77>

Wang W, Bhole VM, Krishnan E. Chronic kidney disease as a risk factor for incident gout among men and women: retrospective cohort study using data from the Framingham Heart Study. *BMJ Open* 2015;5:e006843. doi:10.1136/bmjopen-2014-006843

## LAMPIRAN

### Lampiran 1 Surat Permohonan Izin Penelitian



KEMENTERIAN PENDIDIKAN KEBUDAYAAN,  
RISET DAN TEKNOLOGI  
UNIVERSITAS HASANUDDIN  
FAKULTAS KEDOKTERAN  
JL. PERINTIS KEMERDEKAAN KM. 10, MAKASSAR 90245  
TELEPON (0411) 586200, (6 SALURAN), 584200, FAX (0411) 585188  
Laman: www.unhas.ac.id

Nomor : 11545/UN4.6.8/PT.01.04/2024  
Hal : Permohonan Izin Penelitian

12 Juni 2024

Yth. Direktur RSUP Dr. Wahidin Sudirohusodo

Dengan hormat, disampaikan bahwa mahasiswa Program Studi Pendidikan Dokter Fakultas Kedokteran Universitas Hasanuddin di bawah ini :

N a m a : Zafirah Fitri Aiko Zulfajri  
N i m : C011211089

bermaksud melakukan penelitian di RSUP Dr. Wahidin Sudirohusodo dengan judul penelitian "Hubungan Kadar Serum Asam Urat pada Pasien Penyakit Ginjal Kronik dengan Kejadian Arthritis Gout di RS Dr. Wahidin Sudirohusodo Tahun 2023"

Sehubungan hal tersebut kiranya yang bersangkutan dapat diberi izin untuk melakukan Penelitian dalam rangka penyelesaian studinya.

Demikian permohonan kami, atas bantuan dan kerjasamanya disampaikan terima kasih.

Ketua Program Studi S1  
Pendidikan Dokter  
Fakultas Kedokteran



dr. Ririn Nislawati, M.Kes.,Sp.M  
NIP 198101182009122003



**Lampiran 2 Pengantar Rekomendasi Etik**

KEMENTERIAN PENDIDIKAN KEBUDAYAAN,  
RISET DAN TEKNOLOGI  
UNIVERSITAS HASANUDDIN  
FAKULTAS KEDOKTERAN  
JL. PERINTIS KEMERDEKAAN KM. 10, MAKASSAR 90245  
TELEPON (0411) 586200, (6 SALURAN), 584200, FAX (0411) 585188  
Laman: www.unhas.ac.id

Nomor : 11544/UN4.6.8/KP.06.05/2024

12 Juni 2024

Hal : Pengantar Untuk Mendapatkan Rekomendasi Etik

Yth. Ketua Komisi Etik Penelitian Kesehatan FK Unhas

Dengan hormat, disampaikan bahwa mahasiswa Program Studi Sarjana Kedokteran Fakultas Kedokteran Universitas Hasanuddin di bawah ini :

N a m a : Zafrah Fitri Aiko Zulfajri  
N i m : C011211089

bermaksud melakukan penelitian dengan Judul "Hubungan Kadar Serum Asam Urat pada Pasien Penyakit Ginjal Kronik dengan Kejadian Arthritis Gout di RS Dr. Wahidin Sudirohusodo Tahun 2023"

Untuk maksud tersebut di atas, kami mohon kiranya yang bersangkutan dapat diberikan surat rekomendasi etik dalam rangka penyelesaian studinya.

Demikian permohonan kami, atas bantuan dan kerjasamanya disampaikan terima kasih.

Ketua Program Studi S1  
Pendidikan Dokter  
Fakultas Kedokteran

















dr. Ririn Nislawati, M.Kes.,Sp.M  
NIP 198101182009122003



## Lampiran 3 Etik Penelitian

 KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN RSPTN UNIVERSITAS HASANUDDIN RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR Sekretariat : Lantai 2 Gedung Laboratorium Terpadu JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245. Contact Person: dr. Agussalim Bukhari, MMed, PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431			
<b>REKOMENDASI PERSETUJUAN ETIK</b>			
Nomor : 498/UN4.6.4.5.31/ PP36/ 2024			
Tanggal: 2 Juli 2024			
Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :			
No Protokol	UH24060477	No Sponsor	
Peneliti Utama	Zafirah Fitri Aiko Zulfajri	Sponsor	
Judul Peneliti	Hubungan Kadar Serum Asam Urat pada Pasien Penyakit Ginjal Kronik dengan Kejadian Arthritis Gout di Rumah Sakit Umum Pusat Dr. Wahidin Sudirohusodo Tahun 2023		
No Versi Protokol	1	Tanggal Versi	27 Juni 2024
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RSUP. Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	<input checked="" type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 2 Juli 2024 sampai 2 Juli 2025	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Prof. dr. Muh Nasrum Massi, PhD, SpMK, Subsp. Bakt(K)	 	
Sekretaris KEP Universitas Hasanuddin	dr. Firdaus Hamid, PhD, SpMK(K)		
Kewajiban Peneliti Utama:			
<ul style="list-style-type: none"> <li>Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan</li> <li>Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan</li> <li>Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah</li> <li>Menyerahkan laporan akhir setelah Penelitian berakhir</li> <li>Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)</li> <li>Mematuhi semua peraturan yang ditentukan</li> </ul>			

## Lampiran 4 Rekapitulasi Data Penelitian

	 NORM	 Usia	 PemAU	 KO DE	 riwayat	 Hiperten si	 DM
1	1494	64	7.6	N18.5	non gout	non HT	non dm
2	1517	45	10.0	N18.3	gout	non HT	non dm
3	1785	62	8.4	N18.5	gout	HT	non dm
4	1683	58	11.0	N18.4	non gout	HT	DM
5	1743	32	4.9	N18.5	non gout	HT	non dm
6	1771	55	5.1	N18.5	non gout	non HT	non dm
7	1120	38	3.6	N18.5	non gout	non HT	non dm
8	1602	52	5.3	N18.5	non gout	HT	DM
9	1853	26	5.5	N18.5	non gout	non HT	non dm
10	1435	59	4.3	N18.5	non gout	non HT	non dm
11	1476	69	12.0	N18.5	non gout	non HT	non dm
12	1604	32	2.1	N18.5	non gout	non HT	non dm
13	1610	72	14.1	N18.5	non gout	non HT	non dm
14	1755	72	9.9	N18.5	non gout	non HT	non dm
15	1442	70	11.5	N18.4	gout	non HT	non dm
16	1238	57	12.9	N18.3	gout	non HT	non dm
17	1248	33	18.7	N18.5	non gout	non HT	non dm
18	1848	67	6.8	N18.5	non gout	non HT	non dm
19	1709	27	8.7	N18.5	non gout	non HT	non dm
20	1348	54	14.1	N18.5	gout	non HT	non dm
	 NORM	 Usia	 PemAU	 KO DE	 riwayat	 Hiperten si	 DM
21	1863	62	10.8	N18.5	gout	non HT	non dm
22	1508	48	4.3	N18.5	non gout	non HT	non dm
23	1755	66	9.4	N18.5	non gout	non HT	non dm
24	1027	41	7.8	N18.5	non gout	non HT	non dm
25	1323	62	9.1	N18.5	non gout	non HT	non dm
26	1111	61	17.4	N18.9	non gout	non HT	non dm
27	1460	37	5.9	N18.5	non gout	non HT	non dm
28	1896	41	7.7	N18.5	non gout	non HT	non dm
29	1152	64	3.3	N18.5	gout	non HT	non dm
30	1567	49	15.9	N18.5	gout	non HT	non dm
31	1779	72	5.8	N18.5	non gout	non HT	non dm
32	1464	53	11.2	N18.5	gout	non HT	non dm
33	1715	41	8.6	N18.5	non gout	non HT	non dm
34	1944	46	9.8	N18.5	non gout	non HT	non dm
35	1255	72	8.5	N18.4	gout	non HT	non dm
36	1147	54	8.1	N18.5	gout	non HT	DM
37	1235	60	7.9	N18.5	non gout	non HT	non dm
38	1384	34	9.8	N18.5	non gout	non HT	DM
39	1835	32	7.5	N18.5	gout	non HT	non dm
40	1106	65	11.5	N18.5	non gout	non HT	non dm



	NORM	Usia	PemAU	KO DE	riwayat	Hipertensi	DM
41	178	59	11.4	N18.4	non gout	non HT	non dm
42	570	40	7.4	N18.5	non gout	non HT	non dm
43	949	62	18.6	N18.5	non gout	HT	non dm
44	556	21	10.9	N18.5	non gout	non HT	DM
45	625	45	18.6	N18.5	non gout	non HT	non dm
46	892	50	11.8	N18.5	gout	non HT	non dm
47	996	60	8.6	N18.5	non gout	non HT	DM
48	918	51	10.8	N18.9	non gout	non HT	non dm
49	533	76	12.8	N18.5	non gout	non HT	non dm
50	026	72	10.8	N18.3	non gout	non HT	non dm
51	550	74	7.0	N18.9	non gout	HT	DM
52	830	57	11.5	N18.5	non gout	non HT	non dm
53	614	73	7.4	N18.5	non gout	non HT	non dm
54	257	67	7.5	N18.5	non gout	non HT	non dm
55	317	56	10.7	N18.3	gout	non HT	non dm
56	971	43	9.6	N18.5	non gout	non HT	non dm
57	782	33	7.5	N18.5	non gout	non HT	non dm
58	736	55	23.1	N18.5	non gout	non HT	non dm
59	481	58	4.1	N18.5	non gout	non HT	non dm
60	089	19	5.2	N18.5	non gout	non HT	non dm
	NORM	Usia	PemAU	KO DE	riwayat	Hipertensi	DM
61	983	36	6.4	N18.5	non gout	non HT	non dm
62	318	58	8.2	N18.3	gout	non HT	non dm
63	784	75	8.8	N18.3	gout	HT	non dm
64	904	61	13.1	N18.3	non gout	non HT	non dm
65	235	60	6.4	N18.5	non gout	non HT	non dm
66	229	68	9.8	N18.4	non gout	non HT	DM
67	549	29	10.2	N18.5	non gout	non HT	non dm
68	542	61	4.1	N18.5	non gout	non HT	non dm
69	187	29	6.4	N18.5	non gout	non HT	non dm
70	033	50	7.8	N18.5	non gout	HT	non dm
71	935	75	7.0	N18.5	non gout	non HT	non dm
72	698	48	7.0	N18.5	non gout	non HT	non dm
73	901	50	12.1	N18.5	non gout	non HT	non dm
74	680	74	12.3	N18.9	non gout	non HT	non dm
75	719	45	7.9	N18.5	non gout	non HT	non dm
76	156	50	6.9	N18.5	non gout	non HT	non dm
77	167	31	5.0	N18.5	non gout	non HT	non dm
78	714	41	7.1	N18.5	non gout	non HT	non dm
79	362	61	6.3	N18.5	non gout	non HT	non dm
80	459	49	6.1	N18.9	non gout	non HT	non dm

## Lampiran 5 Excell dan SPSS

### Sebaran Sampel Berdasarkan Usia

		<b>kode_usia1</b>			
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Dewasa awal	16	20.0	20.0	20.0
	Dewasa tengah	33	41.3	41.3	61.3
	Dewasa akhir	13	16.3	16.3	77.5
	Usia lanjut	18	22.5	22.5	100.0
	Total	80	100.0	100.0	

### Sebaran Sampel Berdasarkan Kadar Asam Urat

		<b>kode_AU</b>			
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	normourisemia	25	31.3	31.3	31.3
	hiperurisemia	55	68.8	68.8	100.0
	Total	80	100.0	100.0	

### Sebaran Sampel Berdasarkan Stadium Penyakit Ginjal Kronik

		<b>grading</b>			
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	CKD Grade 3	7	8.8	8.8	8.8
	CKD Grade 4	5	6.3	6.3	15.0
	CKD Grade 5	68	85.0	85.0	100.0
	Total	80	100.0	100.0	

### Sebaran Sampel Berdasarkan Diagnosis Gout

		<b>riwayat1</b>			
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	non gout arthritis	64	80.0	80.0	80.0
	gout arthritis	16	20.0	20.0	100.0
	Total	80	100.0	100.0	

Sebaran Sampel Berdasarkan Riwayat Hipertensi

### Hipertensi

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	non HT	72	90.0	90.0	90.0
	HT	8	10.0	10.0	100.0
	Total	80	100.0	100.0	

Sebaran Sampel Berdasarkan Riwayat Diabetes Melitus

### DM

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	non dm	72	90.0	90.0	90.0
	DM	8	10.0	10.0	100.0
	Total	80	100.0	100.0	

Tabulasi Silang Usia Dan Stadium PGK

<b>Kode_usia * kode_grading Crosstabulation</b>						
			kode_grading			Total
			CKD 3	CKD 4	CKD 5 ESRD	
Kode_usia	dewasa awal	Count	0	0	1	1
		% of Total	0.0%	0.0%	6.3%	6.3%
	dewasa tengah	Count	4	0	5	9
		% of Total	25.0%	0.0%	31.3%	56.3%
	dewasa akhir	Count	0	0	3	3
		% of Total	0.0%	0.0%	18.8%	18.8%
	usia lanjut	Count	1	2	0	3
		% of Total	6.3%	12.5%	0.0%	18.8%
Total		Count	5	2	9	16
		% of Total	31.3%	12.5%	56.3%	100.0%

Tabulasi Silang Kadar Asam Urat Dan Stadium PGK

		<b>KadarAU * GradeCKD Crosstabulation</b>				
		GradeCKD			Total	
		CKD Grade 3	CKD Grade 4	CKD Grade 5		
KadarAU	normourisemia	Count	0	0	25	25
		% within KadarAU	0.0%	0.0%	100.0%	100.0%
		% within GradeCKD	0.0%	0.0%	36.8%	31.3%
		% of Total	0.0%	0.0%	31.3%	31.3%
	hiperurisemia	Count	7	5	43	55
		% within KadarAU	12.7%	9.1%	78.2%	100.0%
		% within GradeCKD	100.0%	100.0%	63.2%	68.8%
		% of Total	8.8%	6.3%	53.8%	68.8%
	Total	Count	7	5	68	80
		% within KadarAU	8.8%	6.3%	85.0%	100.0%
		% within GradeCKD	100.0%	100.0%	100.0%	100.0%
		% of Total	8.8%	6.3%	85.0%	100.0%

Tabulasi Silang Asam Urat Dan Diagnosis Gout

		<b>KadarAU * diagnose_gout Crosstabulation</b>			
		diagnose_gout		Total	
		non gout arthritis	gout arthritis		
KadarAU	normourisemia	Count	24	1	25
		% within KadarAU	96.0%	4.0%	100.0%
		% within diagnose_gout	37.5%	6.3%	31.3%
		% of Total	30.0%	1.3%	31.3%
	hiperurisemia	Count	40	15	55
		% within KadarAU	72.7%	27.3%	100.0%
		% within diagnose_gout	62.5%	93.8%	68.8%
		% of Total	50.0%	18.8%	68.8%
	Total	Count	64	16	80
		% within KadarAU	80.0%	20.0%	100.0%
		% within diagnose_gout	100.0%	100.0%	100.0%
		% of Total	80.0%	20.0%	100.0%

Tabulasi Silang Stadium PGK Dan Diagnosis Gout

			diagnose_gout		Total
			non gout arthritis	gout arthritis	
GradeCKD	CKD Grade 3	Count	2	5	7
		% within GradeCKD	28.6%	71.4%	100.0%
		% within diagnose_gout	3.1%	31.3%	8.8%
		% of Total	2.5%	6.3%	8.8%
	CKD Grade 4	Count	3	2	5
		% within GradeCKD	60.0%	40.0%	100.0%
		% within diagnose_gout	4.7%	12.5%	6.3%
		% of Total	3.8%	2.5%	6.3%
	CKD Grade 5	Count	59	9	68
		% within GradeCKD	86.8%	13.2%	100.0%
		% within diagnose_gout	92.2%	56.3%	85.0%
		% of Total	73.8%	11.3%	85.0%
Total	Count	64	16	80	
	% within GradeCKD	80.0%	20.0%	100.0%	
	% within diagnose_gout	100.0%	100.0%	100.0%	
	% of Total	80.0%	20.0%	100.0%	

Hasil Analisis Chi Square Usia Dan Stadium PGK

<b>Chi-Square Tests</b>			
	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	7.790 <sup>a</sup>	6	.254
Likelihood Ratio	9.951	6	.127
Linear-by-Linear Association	2.114	1	.146
N of Valid Cases	80		

a. 8 cells (66.7%) have expected count less than 5. The minimum expected count is .81.

Hasil Analisis Chi Square Kadar Asam Urat Dan Stadium PGK

### Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	6.417 <sup>a</sup>	2	.040
Likelihood Ratio	9.928	2	.007
Linear-by-Linear Association	5.688	1	.017
N of Valid Cases	80		

a. 4 cells (66.7%) have expected count less than 5. The minimum expected count is 1.56.

Hasil Analisis Spearman Rho Kadar Asam Urat, Stadium PGK Terhadap Diagnosis Gout

### Correlations

		riwayat1	kode_AU	grading	
Spearman's rho	riwayat1	Correlation Coefficient	1.000	.270 <sup>*</sup>	-.415 <sup>**</sup>
		Sig. (2-tailed)	.	.016	.000
		N	80	80	80
	kode_AU	Correlation Coefficient	.270 <sup>*</sup>	1.000	-.281 <sup>*</sup>
		Sig. (2-tailed)	.016	.	.011
		N	80	80	80
	grading	Correlation Coefficient	-.415 <sup>**</sup>	-.281 <sup>*</sup>	1.000
		Sig. (2-tailed)	.000	.011	.
		N	80	80	80

\*. Correlation is significant at the 0.05 level (2-tailed).

\*\* . Correlation is significant at the 0.01 level (2-tailed).